PRESSRELEASE

SHIONOGI

Notice Regarding LEO Pharma's Announcement of Approval of Topical JAK Inhibitor Delgocitinib in Mainland China

OSAKA, Japan, November 17, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that LEO Pharma A/S (Head Office: Denmark; Chief Executive Officer: Christophe Bourdon; hereafter "LEO Pharma") has issued a statement to obtaine new drug approval from the National Medical Products Administration (NMPA) of Mainland China for delgocitinib (product name in Japan: CORECTIM®; hereafter "the Product"), a topical Janus kinase (JAK) inhibitor licensed by SHIONOGI to LEO Pharma, for the treatment of adult patients with moderate-to-severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.

This approval is based on positive results from a Phase 3 clinical trial conducted in Mainland China[1,2]. The trial evaluated the efficacy, safety and pharmacokinetics of twice-daily applications of delgocitinib in Chinese adults and adolescents aged 12 and above with moderate to severe chronic hand eczema. The Product met the primary endpoint, showing a statistically significant improvement in disease severity after 16 weeks of treatment compared with vehicle cream.

Chronic hand eczema is a fluctuating disease of the hands and wrists characterized by itch and pain. Symptoms include erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures, and the disease is defined as lasting for more than three months or relapses twice or more within a year. This disease can place a substantial burden on patients, significantly affecting their quality of life (QOL) and daily functioning.

The Product is a non-steroidal topical JAK inhibitor that improves the signs and symptoms of chronic hand eczema by inhibiting the action of JAKs, which play key roles in immune activation signaling in cells, by suppressing overactivation of immune response. Shionogi has entered into a license agreement with LEO Pharma granting exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, and expects to receive royalty income based on sales.

Shionogi has identified "contributing to a healthier and enriched life" as one of its material issues, and is working toward a society in which everyone can live longer, true to themselves, and with vitality. Shionogi will continue to contribute to improving the QOL of patients suffering from various skin diseases.

About Delgocitinib

The product has been approved for LEO Pharma under the brand name Anzupgo® in the United States, the European Union, the United Kingdom, Switzerland, the United Arab Emirates, Canada, Australia, South Korea, and Macau, for the treatment of moderate to severe chronic hand eczema in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
In Japan, SHIONOGI is the marketing authorization holder and Torii Pharmaceutical Co., Ltd. is the distributor, and the two companies co-promote the product under the brand name CORECTIM®. CORECTIM® Ointment

0.5% and CORECTIM® Ointment 0.25% have been approved for atopic dermatitis. In addition, an application for manufacturing and marketing approval for a new 0.5% lotion formulation is currently under review.

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. They deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. They are committed to making a fundamental difference in people's lives, and their broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholders the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,300 people worldwide. "Together, we reach far beyond the skin."
For more information, visit www.leo-pharma.com.

Reference

1. NCT06004050 | A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema | ClinicalTrials.gov
2. LEO Pharma Meets Primary Endpoint in Phase 3 DELTA China Trial with Anzupgo® (delgocitinib) Cream in Chinese Patients with Moderate to Severe Chronic Hand Eczema (CHE) - BioSpace

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html